Mucin is one of the major culprits that hinder drug delivery, and several clinical studies identified that mucin is overexpressed in KRAS-driven pancreatic cancer in mouse and human models [140,141,142,143]. This evidence concerns the gene KRAS and pancreatic neoplasm.